MDM2 and neoplasm: Although inactivating mutations of the Tp53 gene are frequently observed in the majority of SCCs, two cellular signaling pathways involving the MDM2 and E6AP E3s contribute to dampen p53 tumor suppressor activity in p53 proficient SCCs.